<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909515</url>
  </required_header>
  <id_info>
    <org_study_id>202</org_study_id>
    <nct_id>NCT04909515</nct_id>
  </id_info>
  <brief_title>Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.</brief_title>
  <official_title>Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. An International, Open-Label,Uncontrolled, Single-Arm, Multicenter, Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Y-mAbs Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Y-mAbs Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, uncontrolled, international, multi-center, clinical,phase 2 trial, in&#xD;
      patients ≥ 12 months of age with high-risk neuroblastoma in first remission. 120 patients&#xD;
      will be enrolled to receive naxitamab + GM-CSF in combination with isotretinoin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>2-year PFS defined as the proportion of patients alive and without progressive disease (PD) or relapse 2 years after enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>128 weeks</time_frame>
    <description>Progression free survival (defined as time from enrollment until progressive disease/relapse or death, whichever comes first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>1-year progression free survival defined as the proportion of patients alive and without progressive disease or relapse 1 year after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year and 2-year overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>1-year and 2-year overall survival defined as the proportion of patients alive 1 year and 2 years after enrollment, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year event-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>2-year event-free survival, defined as the proportion of patients alive and without progressive disease, relapse, secondary malignancy or until last contact if no event occurred, 2 years after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of positive to negative minimal residual disease (MRD) after 2 cycles</measure>
    <time_frame>6 weeks</time_frame>
    <description>Proportion of patients changing from minimal residual disease positive in bone marrow at enrollment (defined as patients assessed as minimal residual disease positive by RTqPCR of bone marrow at enrollment) to minimal residual disease negative at completion of Cycle 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with MD positive convert to MRD negative</measure>
    <time_frame>6 weeks</time_frame>
    <description>Proportion of patients with disease in bone marrow at enrollment (i.e., minimal disease according to INRC) and convert to minimal residual disease negative (assessed by RTqPCR) at completion of Cycle 2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>naxitamab + GM-CSF + isotretinoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naxitamab</intervention_name>
    <description>3.0 mg/kg/day = 9.0 mg/kg/cycle</description>
    <arm_group_label>naxitamab + GM-CSF + isotretinoin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>250 - 500 microgram/m2/day</description>
    <arm_group_label>naxitamab + GM-CSF + isotretinoin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>160 mg/m2/day</description>
    <arm_group_label>naxitamab + GM-CSF + isotretinoin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documentet neuroblastoma at time of diagnosis defined as&#xD;
&#xD;
               1. Histopathology of solid tumor biopsy, or&#xD;
&#xD;
               2. Bone marrow aspirate or biopsy indicative of neuroblastoma plus high blood or&#xD;
                  urine catecholamine metabolite levels&#xD;
&#xD;
          2. Documented high-risk disease at time of initial diagnosis defined as&#xD;
&#xD;
               1. MYNC-amplified at stage L2, M or MS (according to International Neuroblastoma&#xD;
                  Risk Group (INRG)) of any age or&#xD;
&#xD;
               2. MYCN-nonamplified with stage M (according to INRG) and diagnosed at ≥ 18 months&#xD;
                  of age or&#xD;
&#xD;
          3. Patient must have completed frontline therapy, and achieved one of the following:&#xD;
&#xD;
               1. verified complete response according to INRC (bone marrow positive minimal&#xD;
                  residual disease is allowed as assessed by RTqPCR at site) after completion of&#xD;
                  induction and consolidation with or without autologous stem cell transplantation&#xD;
&#xD;
               2. Verified partial response according to INRC for primary site and soft tissue,&#xD;
                  bone, and bone marrow metastases at pre-autologous stem cell transplantation&#xD;
                  evaluation (i.e., myeloablative chemotherapy + autologous stem cell&#xD;
                  transplantation required as part of frontline regimen). Furthermore, bone marrow&#xD;
                  response must be with ≤ 5% tumor (of total nucleated cellular content) seen on&#xD;
                  any specimen from a bilateral bone marrow aspirate/biopsy and bone response must&#xD;
                  be with ≤ 3 areas of abnormal uptake on 123I-MIBG scintigraphy&#xD;
&#xD;
          4. Age ≥ 12 months at trial enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Verified progressive disease during induction or consolidation therapy&#xD;
&#xD;
          2. Any systemic anti-cancer therapy, including chemotherapy, within 3 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          3. Autologous stem cell transplantation within 6 weeks prior to enrollment or ongoing&#xD;
             toxicity caused by the autologous stem cell transplantation at the discretion of the&#xD;
             Investigator&#xD;
&#xD;
          4. Therapeutic 131I-MIBG within 6 weeks prior to enrollment&#xD;
&#xD;
          5. Prior anti-GD2 therapy&#xD;
&#xD;
          6. Performance status of &lt; 50% as per the Lansky scale (patients less than 16 years of&#xD;
             age) or Karnofsky scale (patients aged 16 years or older)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joris Wilms</last_name>
    <phone>0045 7026 1414</phone>
    <email>clinicaltrials@ymabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hong Kong Children's Hospital</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <contact>
      <last_name>SVP,Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center Childrens Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center Pediatric Hematology, Oncology and Immunology n.a Dmitry Rogachev</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute of Pediatric Oncology ad Hematology of N.N. Blokhin National Medical Research Center of Oncology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raisa Gorbacheva Memorial Institute of Children Hematology and Transplantation Bone marrow Transplant Clinic</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICON Cancer Centre Novena</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antibody</keyword>
  <keyword>neuroblastoma</keyword>
  <keyword>pediatric</keyword>
  <keyword>naxitamab</keyword>
  <keyword>first remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

